公开(公告)号：US11052091B2

公开(公告)日：2021-07-06

申请号：US16472192

申请日：2017-12-20

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Shingo Yamamoto ,  Masakuni Kurono ,  Atsushi Yoshida ,  Shingo Hotta

IPC分类号： C07D473/14 ,  A61K31/52 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/538 ,  C07D473/16

摘要： The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.

公开(公告)号：US20240270755A1

公开(公告)日：2024-08-15

申请号：US18629648

申请日：2024-04-08

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi Yoshida ,  Ryuichi Hyakutake ,  Nozomu Nagashima ,  Ryosuke Misu ,  Shohei Mori

IPC分类号： C07D495/14 ,  A61P29/00 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D495/14 ,  A61P29/00 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： A drug is provided, which contains, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:




in which all symbols represent the same meaning as the symbols described in the specification.

公开(公告)号：US11981682B2

公开(公告)日：2024-05-14

申请号：US18472970

申请日：2023-09-22

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi Yoshida ,  Ryuichi Hyakutake ,  Nozomu Nagashima ,  Ryosuke Misu ,  Shohei Mori

IPC分类号： A61K31/403 ,  A61P29/00 ,  C07D209/52 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04 ,  C07D495/14 ,  C07D513/04

CPC分类号： C07D495/14 ,  A61P29/00 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6:




in which all symbols represent the same meaning as the symbols described in the specification.